Good afternoon, this is the Chorus Call Conference Operator. Welcome, and thank you for joining the DiaSorin Full Year 2024 Results Conference Call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and zero on their telephone. At this time, I would like to turn the conference over to Mr. Carlo Rosa, CEO of DiaSorin. Please go ahead, sir. Yes, thank you, Operator. Good afternoon, and welcome to the Full Year Conference Call. We're going to make first some comments on the Full Year Results and then move to the quarter four. In 2024, revenue and profitability are in line with the plan, the budget, and the guidance, despite geopolitical tensions and macroeconomic headwinds. Specifically, when it comes to the immunoassay business, we perform very well in the main geography, U.S. and Europe, whereas as we will see later we continue to experience difficult situations in China, although that represents a very small portion of our revenues when it comes to molecular. Molecular overall in the year performed better than the initial assumptions. Clearly, this for us has been a transition year because we launched successfully the LIAISON PLEX with the respiratory panels, and this better result of molecular over the year clearly compensated the LTG software performance compared to expectations because of the life science situations as we have been discussing over the last quarters. Overall, from a pricing perspective, which is something that we did discuss a few times in the last quarters, we've implemented a pricing program that was in place and overcompensate the inflationary effects that we, as an industry, we registered in 2024. Overall, I believe that 2024 was a very good year, and to the point that I remind everybody we raised our guidance twice upward clearly in 2024. Just a couple of comments on the different legs. If we go back to immuno, clearly our U.S. hospital strategy is working well and delivering according to expectation. Let me remind you that our idea was to get to 400 hospitals served by year-end, which was achieved, so we are perfectly in plan with the LTP. The LTP calls for 600 systems installed, 600 hospitals by the end of 2027. When it comes to MeMed, we had the first active 20 custom hospital systems. I need to be very careful here because when it comes to MeMed, we need to talk about the hospital system because placements do follow the concept of hub and spoke, right? Multiple installations between key and LIAISON XL. As we discussed, we do have as a target 75 hospital systems by the end of 2025. When it comes to Europe, 2024 has been a very strong year with double-digit growth as a combination of successful placements, increasing volumes, and outbreaks in certain areas of Europe. Last but not least, we finally started to get regulatory approval for the first products manufactured in China. We expect that by 2026, we are going to have the full menu approved in the Chinese market. If we go to molecular, everybody knows we launched in September our LIAISON PLEX with the respiratory panel. We got a second panel approved shortly thereafter, and we submitted two blood culture panels expecting approval in 2025. In November, I made a comment. I said we had a funnel in the U.S. clearly with 100 customers with equivalent to 500 placements. We are well on track, and we'll discuss later about that. We are well on track to hit our target. The LIAISON PLEX has been received extremely positively by the customers, and I'm going to give more color later when I talk about the quarter. LIAISON NES, we are wrapping up the clinical study as expected, and we're going to be filing within the next quarter or so. Also, LIAISON NES on track. Finally, let me just comment on the LTG. We certainly had a good performance of the LTG business, better than expected, notwithstanding the unfavorable environment in life sciences. In fact, at the end of the year, LTG grew by 3% compared to previous year, clearly driven by very good performance of our diagnostic partners that totally compensated weaknesses in the life sciences that we have seen at the beginning until mid-year 2024. From a 2024 perspective, a very satisfactory result. Now, let's go to quarter four. As usual, I'm going to comment on quarter four at constant exchange rate. We had an excellent quarter. Total revenues, EUR 310 million in the quarter, with a growth of 5% year-on-year in quarter four, excluding COVID, in line with expectations and in line with guidance of 2024 full year. When it comes to COVID, clearly there is a softening of testing. In the quarter, we had EUR 6 million of revenues, EUR 26 million in full year 2024. We see that testing continues to decrease. If now we go to, I would like to comment each individual segment of the business starting from immunodiagnostic. Immunodiagnostic ex-COVID, 6% in the quarter with good performance in US and Europe. You notice a deceleration versus previous quarters, but that is due to TAFCOMP versus Q4 2023 because in Q4 2023, we had exceptional instrument revenues. Indeed, if we go down and look at Core Reagents in a quarter and not Immuno, Core Reagents grew 9% in the quarter. This is net of clearly negative VBP impact in China. In the U.S., in North America, Core grew 14%, and this is related to the hospital strategy where we keep, again, as I said before, expanding our presence in U.S. hospitals. In Europe, in Q4, 8% growth. For Immuno and Core, 9%. We continue to see a very strong growth for our immuno franchise in Europe as well. Export in quarter four was negative, but this is mainly due to the Iran market, where in Q4 last year, we had, again, shipments that did not materialize in Q4. It is a phasing issue. China, we continue to experience headwinds as we have been experiencing since many quarters, double-digit decrease in Q4 as a result of VBP in certain provinces, and the fact that we continue to see overall tough competition coming from local competitors. Clearly, for DiaSorin, China is a very now small percentage of our business moving forward. Long story short, Q4 immunodiagnostic, very strong in North America and very strong in Europe. Tough comparison to last quarter of last year due to some phasing and the fact that we had instrument sales last year related to certain tenders. Now, let's look at molecular diagnostic. Molecular diagnostic in Q4 ex-COVID is pretty much flat, so plus 1% in a quarter. Again, we need to look at the different components of the business separately. When it comes to our targeted molecular business, which is the DiaSorin business, the original DiaSorin business, so the business we bought from Focus, there is a double-digit growth above 20%, and this is thanks to the introduction to the U.S. market of the Candida Auris product, where we continue to see a tremendous traction and success also in 2025. In Q4, I need to remind you that we have discontinued the ARIES platform as part of the plan that was the synergy plan that was presented to the market after the Luminex acquisition. We are missing in Q4 the ARIES revenues, and we had in Q4 2023 last buy orders for ARIES. Again, there is a delta which was expected in this quarter due to the discontinuation of the ARIES. Last but not least, and not surprisingly, as everybody else has reported, mild start of flu season in Q4, but strong Q1. You will see that then in Q1, there is going to be a recovery of the respiratory revenues. Now, let's focus a little bit more on PLEX. Okay? As I said before, full launch started in September 2024. We launched it in the U.S., respiratory. We got first blood culture approved, second, and then the two additional blood culture panels, blood, sorry, blood panels submitted to FDA in September and November 2024. We expect them to be approved by mid-year 2025. GI clinical study ongoing and submission in 2025. This means that as per our long-term plan, by 2026, we're going to have the full multiplexing panel approved on the LIAISON PLEX. In order to guide or explain the way that our business is performing, we decided that moving forward, we are not going to talk about placements, customers, but we are going to talk about total revenues. This is because we look at multiplexing as a franchise, a combination of the VERIGENE, which is a historical business where we are building on, and clearly the LIAISON PLEX, which is the increment, the new platform that we are going to be building on our install base and adding certainly new customers. The launch has been extremely successful, and our ambition for 2025 is that we are going to grow the overall franchise, so VERIGENE plus the PLEX to EUR 75 million. The growth of 25% over prior year is a combination of new accounts and conversion of some respiratory accounts with price increases from the very Gen 1 to the LIAISON PLEX. This corresponds pretty much to the addition of around 150 customers, PLEX customers by year-end. Again, I'm not going to comment any longer from now on in terms of how many customers we add per quarter. I'm just indicating what the budget of DiaSorin today is going to be for PLEX, and I will continue to update the market in total multiplexing revenue growth versus 2024. What's very interesting is that when it comes to the existing customers that are using now the LIAISON PLEX in the U.S., my last comment was that 50%, which I think was November, 50% were flex and 50% were actually fixed. Clearly, moving on, now the situation is that we have more PLEX than fixed, right? And so we see that the adoption of our customer base of the PLEX concept is really providing an advantage versus current solutions that only provide either fixed or mini panels. Last but not least, which is a very interesting, I think, point strategic for DiaSorin, if I look at the current PLEX customer base, 20% are commercial labs and 80% are hospitals. Why is this strategic? Because, as you know, this goes hand in hand with the Immuno strategy, where we intend to continue to develop the hospital business, combination of Immuno and molecular solutions. Just one comment overall, the Verigene other panels, which are so non-respiratory, are relatively flat. Now, finally, final comment, Q4 on LTG. The LTG in Q4 did better than expected. We have a growth of 4% in the quarter, and this is a combination of diagnostic growing, but also we are seeing that the life science is recovering, and we saw also life science slowly growing back in Q4 as well, and we actually continue to see a favorable LTG trend in the first months of 2025. You need to understand that for us, this business is not purely life science, but a combination of partnership with diagnostic and life science and biopharma. We actually serve with this technology three different segments in the market. One more update, which is more on a clinical side of MeMed, which I think is very interesting. There have been a slew of publications that came to the market as a result of independent clinical studies that have been run by MeMed. I think they are available on the MeMed website. I would like to point specifically to three studies, very interesting. The first one has been published on 4,000 patients across 10 different urgent care centers. The key finding of the study is that there is a 63% reduction in unnecessary antibiotic prescription. Seventy percent of previously potentially missed bacterial infection have been now correctly identified. This is a very, very, very important data point to support the adoption of MeMed. The second study on 1,000 patients in 17 centers in the U.S. and Europe, which is very interesting, where they were comparing MeMed to procalcitonin, and the conclusion is that MeMed BV outperforms standard care calcitonin, distinguishing between bacterial and viral infection. Quite often, we get questions from investors about what's different between PCT and BV, and this study clearly shows that MeMed is much better in classifying bacteria versus virus. The third study, which goes more on the pharmacoeconomic side, is demonstrating that there is a significant cost saving up to GBP 250 per patient in case of co-infection if you adopt the MeMed testing prior to administering the antibody. Not only do you have a clinical impact, you also have an economic impact to the hospital budget. All said and done, I'm going to now leave the microphone to Mr. Pedron, our CFO. He's going to drive you through the numbers, and then we're going to go to Q&A. Thank you, Carlo. Good morning. Good afternoon, everybody. Thank you for joining DiaSorin Q4 2024 earnings call and for the interest you are showing in our company. In the next few minutes, I'm going to walk you through 2024 financial performance, and then I will turn the line to the operator for the usual Q&A session. Full year total revenues at EUR 1,185 million are above previous year by 3% or EUR 37 million, despite the expected decrease in COVID sales, which are down by EUR 33 million, and the carve-out of the flow cytometry franchise back in Q1 2023. The business ex-COVID is growing at constant exchange rate by 7%, as we heard. Therefore, in line with the full year guidance, 2024 COVID sales accounted for EUR 26 million vis-à-vis EUR 60 million in 2023, thus broadly in line with our outlook, which was calling for EUR 30 million. The FX impact in the year is negligible. Let's now turn to Q4 revenues ex-COVID at constant exchange rate, which grew by 5% as a result of a solid performance of the new franchise, up by 6%, as we heard, with clear revenues up by 9%, despite what we heard once again happened last year in Q4, actually in 2023 Q4, for the reasons that Carlo just discussed about. We had a good performance of the LTG franchise, up by 4%, thanks to mainly recovering instrument sales, which brings 2024 full year performance of the whole LTG business to 2%, positive 2%. A flattish performance of the molecular franchise, plus 1, where once again the very good start of the LIAISON PLEX RSP panel and the strong growth of the targeted specialty product lines have been offset by the mild beginning of the flu seasons, as per CDC data, and the tough comp with Q4 when we had some last-time buy orders of the ARIES reagents, as discussed a couple of minutes ago. 2024 full year adjusted gross profit at EUR 782 million is better than last year by EUR 33 million or 4%, with a ratio of revenues of 66%, which is better than 2023, which closed at 65%. All the initiatives aimed at improving operation processes and containing costs allowed us to preserve margins despite, as we know, some inflationary pressure, and the manufacturing costs were incurring in our new plant in Shanghai, which has not reached its full capacity production yet. As I said last quarter, I do really believe this is a remarkable indicator of the success of the efforts we put in place to safeguard our profitability. Q4 2024 shows a similar dynamic, both in terms of margins at 66% vis-à-vis 65% of 2023 and growth versus previous year. 2024 adjusted operating expenses at EUR 469 million are basically in line with 2023, with a ratio of revenues of 40% vis-à-vis 41% of last year, confirming the trend we discussed during previous quarter's call. Q4 adjusted OpEX at EUR 125 million are in line with previous year as well. As expected, Q4 is recording an increase in the operating expenses rate compared to the beginning of the year, as we saw last year, by the way, mainly because of the phasing of some projects and throw-up of some costs, mainly health insurance costs in the U.S.. This means, to be clear, that Q4 2024 is higher than the average quarterly rate we should expect for our OpEX during 2025. 2024 other adjusted operating expenses were negative EUR 10 million, therefore recording an increase of EUR 11 million compared to the previous year. This variance is mainly due to a tough comp with 2023, which closed with an income of EUR 1 million as a result of some material one-off positive elements recorded in the previous fiscal year. Additionally, in 2024, there were several one-off expenses which made this variance even wider. I do really believe it is important to consider this substantial swing between 2023 and 2024, driven largely by non-recurring items, to fully appreciate our journey to increasing margins. I will further explore this when I discuss the adjusted EBITDA evolution. As a result of what was just described, full year adjusted EBIT at EUR 303 million or 26% of revenues is higher than 2023 by EUR 20 million or 7%. 2024 adjusted interest income at EUR 4 million is EUR 1 million short compared to 2023 because of the lower yield on our cash balance coming mainly from a reduction on interest rates in the second part of 2024. The adjusted tax rate at 23% is a touch higher than 2023, which closed at 22%. 2024 adjusted net result at EUR 236 million, 20% of revenues, is better than 2023 by EUR 12 million or 5%. Lastly, full year 2024 adjusted EBITDA stands at EUR 394 million or 33% of revenues, which is EUR 19 million better than 2023 and aligns with the full year guidance. Q4 profitability, also 33%, is better than the 32% achieved the previous year. As mentioned earlier, to better appreciate the base business EBITDA margin expansion from 2023- 2024, it's important to consider that in 2023 we had material and non-recurring earning elements in other adjusted operating income. Excluding these, the path to EBITDA margin increase would have been even more apparent. As we will see in a minute, this is confirmed by the 2025 EBITDA guidance, which represents another step forward toward the 2027 margin expansion journey set during the last capital market day. Let me now move to the net financial position. We closed 2024 with a net debt of EUR 618 million, therefore recording an improvement of EUR 159 million compared to the end of 2023, mainly as a result of the very sound free cash flow generated during the year, EUR 241 million vis-à-vis EUR 209 million in 2023. As a result, our net debt to EBITDA ratio is down to 1.6% from the 2.1% we saw at the end of 2023, continuing the deleveraging trajectory shared during the last capital market day. Let me now finish my remarks moving to 2025 guidance, as always expressed at previous year exchange rate. We expect revenues ex-COVID to grow by about 8%, with COVID sales around EUR 20 million and therefore total revenues of the company to grow by about 7%. We also expect an increase in our adjusted EBITDA margin, which in our guidance will be moving from the 33% we had in 2024 to about 34%, which we are guiding for in 2025. Please note that this guidance includes the very recent tariffs which have been introduced and are now enforced between the U.S., Canada, Mexico, and China. Before concluding, let me please remember that DiaSorin financials are highly exposed to the U.S. dollar. As a rule of thumb, consider that for every one cent movement of the dollar against the euro, DiaSorin revenues move by about EUR 6 million - EUR 8 million on a yearly basis, and the adjusted EBITDA moves by EUR 2 million- EUR 3 million. With that said, let me please turn the line to the operator to open the Q&A session. Thank you. Thank you. This is the Chorus Call Conference operator. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on the touch-tone telephone. To remove yourself from the question queue, please press star and two. We kindly ask to pick up your phone when asking questions. Anyone who has a question may press star and one at this time. The first question is from Kavya Deshpande of UBS. Please go ahead. Hi, Carlo. Hi, PG. Thank you for taking my questions. The first one was just on the guidance for 2025. You have obviously had a very strong 2024, but just thinking about some of the headwinds next year, such as the tough kind of European immunodiagnostics comparator, China maybe. When you exclude these, is it fair to say your guide actually probably implies like 9%-10% underlying growth on the top line? Are there any other factors in that 2024 comparator that we should be thinking about when modeling? My second question was just on immunodiagnostics. Your target of 600 hospitals in the U.S. by the end of 2027, when we think about the LIAISON XXL, does that potentially expand that addressable market? Is that how to think about the opportunity going forward from here? Thank you. Hi, Kavya, Yes. Look, I'm trying to resonate on how to answer here. Let's start from the second one, which is easier. The XXL is one of the biggest mistakes that companies can make in diagnostics is to, when you have a very extensive install base, launch a system that is not going to also protect your install base. Because then, clearly, your install base is aging, and the new system is not protecting, and then it's a full recipe for a disaster. Long story short, the XXL, as we've indicated, is providing 30%-35% with several features, right? A 30%-35% increased throughput to the existing XXL. That is fundamentally allowing us on a cost base that is comparable. This is fundamentally allowing us to do two things. For the next 10 years, right, we can expand into the hospital market, laboratory market, and also, since everybody is expecting consolidation, increased volume will allow us to follow the trend. By the same token, it will allow us to go back to the base, our existing 7,000 system install base, and protect that. When that is going to be aging, we will substitute with a new system that fundamentally is the same footprint and better throughput. Long story short, I believe that we will continue to be as a specialist into the same segment, which is pretty much the whole market, because we are today in very large commercial labs. Think about Quest and LabCorp as a specialist with the current XXL, and the XXL will continue to go there. By the same token, we can also serve the mid-segment and high-segment of the hospital market. Now, if I go back to the first question you said, yeah, if I could cancel China from the map and just look at the other market outside China, we expect that we continue to grow double-digit in the main market. The U.S. will continue to be a double-digit market for us, and Europe is going to be a high single-digit market. Australia, Brazil, I mean, everywhere where we are direct, we will continue to see double-digit growth in 2025. When it comes to other geographies where we call export, it clearly is a touch-and-go situation there, because as we saw in Iran, I mean, where we do have presence in certain markets, it goes as it goes, right? I mean, it's a fly-by-night operation in certain situations. However, our expectation for the overall export market, right, ex-Iran, is that that should deliver a growth in immune around 7%, so 6%-7%, right? So it's not going to be so diluted vis-à-vis the rest of the geographies. Thank you very much. Thank you. The next question is from Maja Pataki of Kepler. Please go ahead. Hi, good evening, Carlo, PG, everyone. A couple of questions from my side, please. I would like to start with a bigger picture question, Carlo, on the U.S. On the mess that we're seeing in the U.S., it's great news that you're not going to have any impact from the tariffs. You're solidly positioned from your manufacturing standpoint. There are a couple of things that are moving targets, I understand. Still, it could have a potential impact like vaccination hesitancy, stop of the U.S. aid funds, generally speaking, I guess, a positive for the diagnostic market. On the other hand, discussions on the NIH budget cuts and headcount reductions at the FDA. How do you navigate through the new slow mess, and what kind of push and pulls do you expect to have from everything that is happening in the U.S.? That would be my first question. My second question on China. You are going to have a broader product portfolio manufactured in China as of 2026. How shall we think about China from then on? Is it going to be a growth market for you, or what is it in your plan that is going to happen with China? My last question is, I was trying to take notes. I'm not sure I got it. My understanding was that in the beginning, you said that you are well on track to have 100 customers with LIAISON PLEX by the end of 2025, representing roughly 500 placements. Throughout the call, I thought that you said 150 PLEX customers. Maybe I misunderstood, but I just want to make sure that I know which number to take. Thank you. Hey, Maja, actually, both numbers are correct, but I will go back. Okay. Anyway, it's not that I'm a magician, right? I will explain to you why they are correct. Let's start from the first question, which is the big picture about the U.S. Look, I'm going to say a terrible thing, but actually, if you decrease vaccination, you have outbreaks. You saw the one now in Texas with measles, right? Yeah. Unfortunately, every time vaccination goes down, infection goes up, and we have the kings as DiaSorin of measles, mumps, varicella, herpes, name it, all these kinds of bugs, we do have a very high market share. Unfortunately, if Americans decide to vaccinate less, we're going to benefit, not enjoy, benefit from it. When it comes to the NIH, I mean, your guess is as good as mine guess. So far, clearly, we don't serve the NIH directly, but our partners, Thermo Fisher and Bio-Rad, all these people do serve the NIH. I don't think that today there is any visibility, to be honest with you. I would wait until dust settles. For the time being, as you know, what they've been cutting is budget related to expenses, right? Funding so far has not been cut, but I think they are not allowing now the universities to take more than 15% as overhead, right? Because they say everything else has to be spent in the lab. How that is going to turn, I think we don't know. Also, because every day is a new day in the U.S., right? These days. Let's see. True. FDA, for the time being, we have not seen delays, although we don't know. Okay. Honestly, I mean, every day you read and you hear something different about what's happening in the U.S. For the time being, the FDA has not been an issue for us in terms of vacancies. I will update you a quarter from now, okay? The overall hospital business, private lab, I mean, commercial lab business, we have not seen any impact, and we don't expect to see any impact from at least what we know today, okay? China. China, I think we've been very honest because we were one of the first ones to say that China is going their own way, and I continue to say China will continue to go their own way. This is why for us, it's not strategic any longer. However, as said, we are well positioned if something is going to change because now we're going to have our products made there. We're going to have the LIAISON XXL. We expect that by the end of Q2, we're going to have the China-made LIAISON XXL approved. We submitted, and that clearly will allow us to participate in certain tenders. On the short term, do not hold your breath on China. I mean, it's no good, I think. It's not big damage for DiaSorin. Now, let's go to the magic 100-150. Two different time horizons. I refer to the comment I made in November, right? I said we have a funnel of 100 customers, which correspond to 500 systems. Okay? That's the funnel we are working on. What I said now is that in 2025, our ambition in the U.S. is to have 150 customers running our platforms, right? That correspondence will allow us to increase our multiplexing franchise because what's not obvious is that we do have a few tens of million as we speak of Verigene revenues. Now we look at this franchise, a combination of VERIGENE plus PLEX. Our ambition is to get to $75 million in multiplexing business in the U.S., which does represent a 25% growth versus 2024. Brilliant. Carlo, just one add-up. One of the things that I've forgotten to ask you specifically, if there were any cuts introduced to Medicaid, which I believe is in debate and feared and everything, my understanding is that Medicaid covered patients are roughly 20% of overall covered patients or insured patients in the U.S.. Do you think this is a fair assumption for the overall diagnostic space as well? I was closer to, I thought it was more 30%, to be honest with you. Okay. Okay? So it's slightly higher. But don't forget that in the past, it started with Obamacare and Obama, right? There was actually a program to reduce reimbursement over five years, and it was 30%. So it was a significant number. Eventually, that program was actually stopped by Trump won, right? The discussion has been lingering there. Back then, I keep saying, to be honest with you, Maya, that my concern in the U.S., generally speaking, right, except for any draconian measure, right? My concern when it comes to pricing has to do more with competition rather than the government and reimbursement really driving pricing down significantly. Okay? Okay. My concern, not that much. Okay. Thank you very much. The next question is from Aisyah Noor of Morgan Stanley. Please go ahead. Hi. Good afternoon, Carlo and Piergiorgio. Thanks for taking my question. My first one is on LIAISON PLEX. Thank you for the sales guidance of €75 million for 2025. My question is, what portion of this do you expect to be from the Verigene converted accounts versus new placements? My second question is on China. Apologies if I missed it, but did you provide an update to this EUR 5 million-EUR 6 million impact you anticipate from VBP in 2025? If so, could you just provide some color around the timing of this VBP, what regions are affected, or any impact you anticipate on a more broader scope of targets? My last question is on your outlook for the immune business. Just trying to understand the mix of the growth drivers in that portfolio between QuantiFERON, MeMed, Lyme. What are the biggest components that could drive the move the needle the most for immunogrowth this year? Thank you. Okay. Let me start with the first question. I decided that what's very relevant for DiaSorin is when it comes to multiplexing, at the end of the story, it's a combination of technologies. Where is it that we want to be at the end of 2027, right? We said we want to have 10% market share. Pretty much it's EUR 200 million, give or take, right? This is the way we drive the business, and this is the way I want to explain the business to the investors. Otherwise, if I get into how many, how much are you converting, what's the price increase, believe me, each analyst and every investor is going to do a different calculation, and I will spend more time trying to correct mistakes rather than look at what's relevant for the business. Track it. The $75 million this year will become $200 million, and this is what we are targeting. Okay? Second question, China VBP, it's a very short answer. Now, $5 million-$6 million already started in Q1 because VBP now has been extended from the original panel. Now they went also to, they included more assays, right? The overall effect for DiaSorin yearly is around $5-6 million in 2025. Third question is immuno. I keep saying that the beauty of DiaSorin is that we are not a one-trick pony. As we know, I learned that expression in 2015 when vitamin D was 44% of our revenues. We are far off the one-trick pony story. We win and we retain customers because we have an offering of specialties that go across many different segments. Okay? Certainly, QuantiFERON is a door opener and is a relevant assay to have in the hospital market because hospitals are doing QuantiFERON. Actually, as we discussed a few times, hospitals are sending out QuantiFERON, and now they have the ability with the better technology to do it in-house. Stool is a tremendous opportunity because IBD, IBS is exploding as a market, and we are very well positioned today to allow this growing volume to be done effectively on our platform. We have a lot to say when it comes to the Calprotectin 3.0 that is going to be, in my opinion, a revolution in the ability to properly diagnose IBD and IBS. You have all the infectious disease panel that follows suit. Let me just give you an example, which is not trivial. Take hepatitis HIV. Hepatitis HIV is one of the most commonized menu you can imagine because Abbott, Siemens, Roche, you name it, they all have it. Our revenues, our hepatitis franchise in the U.S. as a result of the fact that we are expanding the stall base in hospitals, and every hospital is doing hepatitis. Today, that business is close to EUR 60 million-EUR 70 million and is growing more than double digit. Okay. You are saying what is driving DiaSorin success is a combination of certain specialties and all the meat products, very good quality. We have an infectious disease that follows suit as long as you start with the conversation with Stool, with TB, and now with MeMed. I made a comment already, as you know, that MeMed today is not many dollars, but a ton of interest by customers to talk to DiaSorin and drives placements of existing menu waiting for validation of MeMed to be completed. Understood. Thank you very much. The next question is from Dylan van Haaften of Stifel. Please go ahead. Hi guys. This is Dylan. Good afternoon. Just two from me. Firstly, just on molecular, and we spoke about the respiratory season, and I think, I mean, we knew there was going to be delayed season. I was just wondering, maybe we're expecting slightly stronger visibility just on PLEX, maybe with more pre-buying happening in the Q4 relative to the Q1. Any commentary there on, I guess, the purchasing patterns? I guess then secondly, just to check, just on the numbers of Verigene, I think you said it was a double-digit number underlying. If we think about the 75 million number, then essentially, is it fair to say like PLEX is like most single digit, maybe even slightly higher incremental growth, let's say, onto your year-on-year growth? Is that kind of the way we should kind of think about it? Is there anything outside of the China weakness and dollar weakness that you want to flag that gets you closer to sort of that 8% that you're guiding right now? Is there anything we haven't spoken about in this call so far? Dylan, I'm for the first question and third. When it comes to purchasing pattern, it's actually the opposite. Hospitals do not tend to buy in season because they don't have time to validate. This is very interesting because notwithstanding that pattern, that hospitals don't want to switch during the season, and we launched the system fundamentally during the season, we are having strong success notwithstanding the fact that hospitals don't have a lot of time to validate, right? The data that you see is not that we upfronted revenues because they bought a lot during the season. It's the opposite. Okay? Your third question, which is 8%, is there any headwind that we didn't take into account? Is that what you were interested to discuss? Sorry. I'll rephrase. It's just that I think if I understand correctly what you're saying about PLEX being incremental, I think it looks like something like 3% incremental growth year on year. Basically everything else looks like business as usual. That would point to something like on an underlying level that actually feels like it's accelerating, even excluding the China business. I think you said already that much with saying that U.S. and Europe are kind of like Europe is high single digit, U.S. is double digit. I was just wondering how we get to that 8% and whether that's maybe, I mean, obviously we'd ask if that's conservative, but I'm just wondering if that's conservative given just the PLEX number even being incremental. Hey Dylan, this is PG speaking. I will try to take it. Not sure I completely understood your question, but I will do my best. I believe Carlo comments when I was saying double digit and so on and so forth, he was specifically talking about the immuno business because as you might know, our molecular presence in Europe is not as big as in the U.S., even though we are in the process of launching the PLEX in Europe as well, but it's not as big as in the U.S., right? If I can try to broadly, right, to dissect for you where this 8% guidance for 2025 is coming from, if I look at our three franchises, immuno, molecular, and LTG, what I think you should imagine is a molecular business to grow at a faster pace than the 8% because you will see the impact of what Carlo has been discussing about. This is, by the way, in line with our long-term plan when we guided the molecular franchise to grow low double digit increase, right? You should expect the immuno franchise to grow more or less at the same pace of our full year guidance, right? Which is once again in line with our long-term plan when we said the high single digit, that was how we guided the market. LTG, and do not look at LTG every quarter because we have some bulk shipments which can skew one quarter up and the following quarter down. For the LTG franchise, you should expect a growth in 2025, which is below the 8% for the full DiaSorin business, right? As a combination of these three franchises, you see the 8% we are guiding for. Awesome. Thank you so much, PG. Thank you. The next question is from Odysseas Manesiotis of BNP Paribas. Please go ahead. Hi. Thanks for taking my questions. Just a couple of modeling ones. On the Q4 immunoassay weakness, just to think about how to model this for this year, factoring in the VBP weakness, is it fair to expect this one to grow higher than Q4 in the coming quarters, but a touch lower than what you grew last year in the first nine months? Secondly, I wanted to get a feeling of how your business is performing in North America ex QuantiFERON-TB, would you say around 8-9% core reagent growth to be a decent estimate for full year 2024, or is it not much of a difference to the 10% you grew in the region last year? And a quick one for PG as well. I remember you saying around EUR 40-50 million in capitalized R&D for 2023. How did that look in 2024, and what should we expect for this year? Thank you. Hey Odysseas, I'm going to take some, but not all of them. For the immuno franchise, what I believe we were hinting when we discussed about China and the staff comp, I believe was very clearly captured by Carlo when he said, "If you look at clear growth in the quarter, you have 9%," which is in line with what we saw in Q1, which resonates with what we saw in Q3, which was 10%. If I look at the growth without China, obviously the growth is even better. I believe that for all of 2025, you will see that 4 million-5 million VBP impact as a headwind, meaning that the underlying business obviously is doing better. That means once again that once that VBP effect is, let me say, under the belt, you are not going to see that headwind any longer. For the growth in North America without the QuantiFERON business, I'm not going to comment there. I believe as Carlo said, I refer to what Carlo said, meaning that we are not a one-trick pony. We have several business lines which are doing very, very well in our immuno franchise in the U.S.. QuantiFERON is definitely one of those, but we have much, much, much more. I'm sorry, Odysseas, I don't remember. Oh yeah, the CapEx, R&D. I believe the right way to think about it is that in 2024, you see the peak in terms of R&D CapEx because we are at the, let me say, the highest point of our effort of bringing new platform and new products to the market. Think about the PLEX, which has been launched now. Think about the NES. Think about all the clinical studies to support the different panels and products that we're going to launch. I'm expecting a deceleration, and that's budgeted for, by the way, in 2025, of that R&D CapEx, and even a farther and steeper deceleration in 2026 and in 2027, right? Simply because we will go back to, let me say, normal business, if I can use that word, because now we are working on several different platforms at the same time and several different panels. If overall you think about our CapEx in 2024, which is around EUR 130 million as a combination of R&D instruments we are placing in customer premises, which are staying in our books, I'm expecting that number, and that's also included in our long-term plan, to decrease materially, not so much in 2025, where we will see anyway a deceleration, but even more so in 2026 and in 2027. The next question is from Natalia Webster of RBC Capital Markets. Please go ahead. Hi. Thanks for taking my questions. Just following up on some of the previous ones around the expectations into 2025, I wanted to check if you're still confident in your midterm guidance for the high single digit to low double digit sales target 2027 and the specific segmental guidance you provided within this, particularly on licensed technologies. You said you're expecting this to be lower than the group 8% in 2025, but are you expecting this to reach the sort of mid to high single digit level that you guided for the midterm now that you're seeing some recovery from life sciences? Thank you. Hey Natalia, hi. This is PG speaking. Yes. I mean, absolutely. We feel very comfortable with the midterm guidance we gave, and I believe the fact that we grew already in 2024, the business excluded by 7% is very clear, and we are guiding for 2025 at 8%. It's very clear in. Without the impact of the PLEX, then all of those programs which are coming our way, I believe we feel very, very comfortable with the high single to low double digit guidance we gave for the midterm. Absolutely. Very, very comfortable with that. You can obviously have some, let me say, little movement amongst the three different technologies. Very difficult to say what's going to happen for the licensed technology. What we saw is that we closed 2024 with a plus 2%, but as Carlo was saying, if you look at the performance of the diagnostics business, there is high single, mid to high single. It's actually 7%, right? We've had the headwind for the life science business that everybody has discussed about. How long is that going to last? Very difficult to say, but I believe we are kind of shielded there compared to pure life science company for the reasons we've discussed. The mid, let me say, the mid of the mid to high single digit number we gave for during the capital market day, I believe it's absolutely at reach. Barring the fact that once again, these days it's very difficult to make predictions about what's going to happen in the U.S., but that's how we see it. Thank you. That's helpful. I guess just the same question on the margin. I mean, you're guiding to expansion to 34% in 2025, but are you still confident on that 36%-37% target for 2027? Also, just following up, apologies if I missed it, but did you quantify the impact you're assuming from tariffs as well? Also for margin, we do feel very, very comfortable with the midterm guidance. We closed 2024 with 33%, and by the way, the guidance was upgraded, reviewed upward during the year. The budget for 2024, the guidance for 2025 is 34%, so we are absolutely in the trajectory I was telling you to 36%-37%, and no doubt there. For the tariffs, the impact of what has already been approved by the Trump administration and the counter tariffs put in place by Mexico, China, and Canada is negligible. It's embedded in our guidance, but it's negligible because as you know, most of the products we sell in the U.S. are manufactured in the U.S.. We have a very big manufacturing footprint there. As things are today, we don't see issues. Great. Thank you. The next question is from Jan Koch of Deutsche Bank. Please go ahead. Good afternoon. Thanks for taking my questions. I have three, if I may. I'm hoping to find my luck on the PLEX again. The EUR 75 million you mentioned as a target for multiplex, does that assume negative growth of your very routine business in 2025? Secondly, of the customers that have already received a PLEX system, how many slots do they activate on average? Finally, coming to the tariff question again, thanks for providing the comments on the potential impact. In case the situation escalates further, how easy is it for you to pass on additional costs to your customers? Are there any differences between your segments in terms of pricing power? Again, sorry, I do not want to annoy anybody, but I have no intention whatsoever to enter into detail of cannibalization, price increase, and so forth because it is very confusing when it comes to PLEX. I kept saying we have a target to get to EUR 200 million in the plan, and next year the EUR 200 million talks to the EUR 75 million target, which is a combination of new accounts, conversion of existing account, price increase, and so forth. Okay? When it comes to the second question, it has to do with tariffs? Yeah, it was the third. The second was about PLEX customers, but I'm not sure I completely understood what the question was. I understood the third one. The third one is, so I can start taking the third one about tariffs. What I said is the current guidance for 2025 does include the new tariffs, which have already been, let me say, which became a reality, right, because of what the Trump administration did and the counter tariffs from China, from Canada, from Mexico. What's going to happen in the future? Man, it's very difficult to say. Very, very difficult to say. Yeah. I believe the question was, would you have pricing power to offset those tariffs? And how can you allocate a different pricing power by segment? I guess that was the question, right? Ian? Yep. Listen, if I may take one, during the inflation, I think our industry as everybody else learned that there is a rationale behind you are allowed to increase your pricing, which we did very successfully. If there is an increase due to tariffs, the whole industry is going to go back and put pressure on the customers for price increases, right? This is what exactly everybody's saying. Eventually, all these tariffs will bring more inflation because of price increases. We will do all we can by contract to achieve that. Okay. Understood. Maybe in terms of the second question, let me rephrase that one. Given that the PLEX has six slots, how many slots are being used by an average customer so far? What we are seeing so far is that many customers are asking to have most of the slots filled, let me put it in that way, meaning that most of the chassis, that's how we call the frame, right, that our customers are installing are filled with all of the slots, all of the available slots. Understood. Thank you. Thank you. The next question is from Shubhangi Gupta of HSBC. Please go ahead. Hi. Thanks for taking my question. My first question is on the LTG business. It is more of a clarification. You mentioned you're seeing some improvement in the life science as well as the biopharma segment. Could you give some color on what portion is life science and what portion is biopharma? Second, on the molecular diagnostic business. In Q4 sequentially, could you give some color on the growth of instruments versus reagents for Q4 versus Q3? Hey, hi. This is PG. I will take it. Broadly speaking, when you think about our LTG business, 50%, half of it is represented by diagnostic companies, diagnostic companies, right? Fifty percent is what we call life science, biopharma, academia, research, all the rest, right? What we said is on the 50%, which is diagnostics, we are very protected because you do not see the headwind that you see on the life science. We are not sharing numbers of exactly how much we saw increase or decrease in instruments or royalties or bids, but the main message is where we suffer the most in 2024 is on instrument sales, like most of the industry capex, let me say. Whereas we did not see such, let me say, a headwind on bids and royalties because of the installed base, obviously, which keeps pulling bids. Thank you. Just a quick follow-up on the LTG business. You have some exposure to the academic customers. Is that direct exposure? I know this has been covered earlier, but do you have any direct exposure to NIH because you have exposure to academic customers? No. First, you need to understand it is B2B. We do not know where these instruments are going to because we sell it to Thermo Fisher, we sell it to Bio-Rad, we sell it to Biotechnique, and they go and they sell themselves, right? We do not know if there is a big exposure with the NIH. What I know, what we see is that there is a good chunk of the systems that are actually going outside the U.S. first. Second, because we sell to a partner in the U.S. and they distribute worldwide, the second thing that we see is that there is a growing biopharma business for them. Okay? When it comes to the NIH exposure, as I said, I think before, we need to wait for their comment in Q1. We will learn from them how they see the NIH situation. Mr. Rosa, Mr. Pedron, there are no more questions registered at this time. Thank you, operator. Bye-bye. Thank you. Bye. Ladies and gentlemen, thank you for joining. The conference is now over. You may disconnect your telephones. Thank you.